Inhibition of intestinal FXR activity as a possible mechanism for the beneficial effects of a probiotic mix supplementation on lipid metabolism alterations and weight gain in mice fed a high fat diet

• Published in: Gut microbes 2023-12, Vol.15 (2), p.2281015
• Main Authors: Beau, Alice, Benoit, Bérengère, Le Barz, Mélanie, Meugnier, Emmanuelle, Penhoat, Armelle, Calzada, Catherine, Pinteur, Claudie, Loizon, Emmanuelle, Chanon, Stéphanie, Vieille-Marchiset, Aurélie, Sauvinet, Valérie, Godet, Murielle, Laugerette, Fabienne, Holowacz, Sophie, Jacouton, Elsa, Michalski, Marie-Caroline, Vidal, Hubert
• Format: Article
• Language: English
• Subjects: Animals; bifidobacterium animalis; bile acids; Bile Acids and Salts - metabolism; Diet, High-Fat - adverse effects; Gastrointestinal Microbiome; gut microbiota; high-fat diet; Human health and pathology; Hépatology and Gastroenterology; intestinal FXR signaling; lactobacillus gasseri; Life Sciences; Lipid Metabolism; Liver - metabolism; Metabolic syndrome; Mice; Mice, Inbred C57BL; Microbiology and Parasitology; Probiotics - pharmacology; Probiotics - therapeutic use; Research Paper; RNA, Messenger - metabolism; RNA, Messenger - pharmacology; Triglycerides; Weight Gain
• ISSN: 1949-0976; 1949-0984; 1949-0984
• DOI: 10.1080/19490976.2023.2281015

Supplementation with probiotics has emerged as a promising therapeutic tool to manage metabolic diseases. We investigated the effects of a mix of Bifidobacterium animalis subsp. lactis LA804 and Lactobacillus gasseri LA806 on high-fat (HF) diet -induced metabolic disease in mice. Supplementation with the probiotic mix in HF diet-fed mice (HF-Pr2) reduced weight and fat mass gains, decreased hepatic lipid accumulation, and lowered plasma triglyceride peak during an oral lipid tolerance test. At the molecular level, the probiotic mix protected against HF-induced rise in mRNA levels of genes related to lipid uptake, metabolism, and storage in the liver and white adipose tissues, and strongly decreased mRNA levels of genes related to inflammation in the white adipose tissue and to oxidative stress in the liver. Regarding intestinal homeostasis, the probiotic mix did not prevent HF-induced gut permeability but slightly modified microbiota composition without correcting the dysbiosis induced by the HF diet. Probiotic supplementation also modified the cecal bile acid (BA) profile, leading to an increase in the Farnesoid-X-Receptor (FXR) antagonist/agonist ratio between BA species. In agreement, HF-Pr2 mice exhibited a strong inhibition of FXR signaling pathway in the ileum, which was associated with lipid metabolism protection. This is consistent with recent reports proposing that inhibition of intestinal FXR activity could be a potent mechanism to overcome metabolic disorders. Altogether, our results demonstrate that the probiotic mix evaluated, when administered preventively to HF diet-fed mice could limit obesity and associated lipid metabolism disorders, likely through the inhibition of FXR signaling in the intestinal tract.